Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 280-289

  Trendowski, Matthew ^a   Mitchell, Joan M ^a   Corsette, Christine M ^a   Acquafondata, Christopher ^a   Fondy, Thomas P ^a  

^a SYRACUSE UNIVERSITY   (United States)

Author keywords

Cytochalasin B; Liposome encapsulation; Lung carcinoma; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHALASIN B; LIPOSOME;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHALASIN B; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; LIPOSOMES; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C;

EID: 84939988796     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0202-6     Document Type: Article

References (27)

1. Scherlach K, Boettger D, Remme N, Hertweck C (2010) The chemistry and biology of cytochalasans. Nat Prod Rep 27(6):869-886
2. Van Goietsenoven G, Mathieu V, Andolfi A, Cimmino A, Lefranc F, Kiss R, Evidente A (2011) In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med 77(7):711-717
3. Trendowski M (2014) The promise of sonodynamic therapy. Cancer Metastasis Rev 33(1):143-160
4. Trendowski M (2014) Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. Biochim Biophys Acta Rev Cancer 1846(2):599-616
5. O'Neill FJ (1972) Chromosome pulverization in cultured normal and neoplastic cells treated with cytochalasin B. J Natl Cancer Inst 49(6):1733-1738
6. Wright WE, Hayflick L (1972) Formation of anucleate and multinucleate cells in normal and SV 40 transformed WI-38 by cytochalasin B. Exp Cell Res 74(1):187-194
7. Kelly F, Sambrook J (1973) Differential effect of cytochalasin B on normal and transformed mouse cells. Nat New Biol 242(120):217-219
8. Trendowski M (2014) Using cytochalasins to improve current chemotherapeutic approaches. Anticancer Agents Med Chem. In press
9. Steiner MR, Altenburg B, Richards CS, Dudley JP, Medina D, Butel JS (1978) Differential response of cultured mouse mammary cells of varying tumorigenicity to cytochalasin B. Cancer Res 38(9):2719-2721
10. Medina D, Oborn CJ, Asch BB (1980) Distinction between preneopastic and neoplastic mammary cell populations in vitro by cytochalasin B-induced multinucleation. Cancer Res 40(2):329-333
11. Somers KD, Murphey MM (1982) Multinucleation in response to cytochalasin B: a common feature in several human tumor cell lines. Cancer Res 42(7):2575-2578
12. Hwang J, Yi M, Zhang X, Xu Y, Jung JH, Kim DK (2013) Cytochalasin B induces apoptosis through the mitochondrial apoptotic pathway in HeLa human cervical carcinoma cells. Oncol Rep 30(4):1929-1935
13. Rao JY, Hurst RE, Bales WD, Jones PL, Bass RA, Archer LT, Bell PB, Hemstreet GP 3rd (1990) Cellular F-actin levels as a marker for cellular transformation: relationship to cell division and differentiation. Cancer Res 50(8):2215-2220
14. Ben-Ze'ev A (1985) The cytoskeleton in cancer cells. Biochim Biophys Acta 780(3):197-212
15. Lipski KM, McQuiggan JD, Loucy KJ, Fondy TP (1987) Cytochalasin B: preparation, analysis in tissue extracts, and pharmacokinetics after intraperitoneal bolus administration in mice. Anal Biochem 161(2):332-340
16. Bousquet PF, Paulsen LA, Fondy C, Lipski KM, Loucy KJ, Fondy TP (1990) Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res 50(5):1431-1439
17. Bogyo D, Fondy SR, Finster L, Fondy C, Patil S, Fondy TP (1991) Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2. Cancer Immunol Immunother 32(6):400-405
18. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5):1444-1454
19. Walling EA, Krafft GA, Ware BR (1988) Actin assembly activity of cytochalasins and cytochalasin analogs assayed using fluorescence photobleaching recovery. Arch Biochem Biophys 264(1):321-332
20. Huang FY, Mei WL, Li YN, Tan GH, Dai HF, Guo JL, Wang H, Huang YH, Zhao HG, Zhou SL, Li L, Lin YY (2012) The antitumour activities induced by pegylated liposomal cytochalasin D in murine models. Eur J Cancer 48(14):2260-2269
21. Trendowski M, Mitchell JM, Corsette CM, Acquafondata C, Fondy TP (2014) Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Investig New Drugs. In Press
22. Rose WC (1981) Evaluation of Madison 109 lung carcinoma as a model for screening antitumor drugs. Cancer Treat Rep 65(3-4):299-312
23. Cerottini JC, Engers HD, Macdonald HR, Brunner T (1974) Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. J Exp Med 140(3):703-717
24. Orsini F, Pavelic Z, Mihich E (1977) Increased primary cell-mediated immunity in culture subsequent to Adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 37(6):1719-1726
25. Lee ST (1980) Statistical methods for survival analysis. Lifetime Learning Publications/Wadsworth Inc
26. Minato H, Katayama T, Matsumoto M, Katagiri K, Matsuura S (1973) Structure-activity relationships among zygosporin derivatives. Chem Pharm Bull (Tokyo) 21(10):2268-2277
27. Katagiri K, Matsuura S (1971) Antitumor activity of cytochalasin D. J Antibiot (Tokyo) 24(10):722-723